0001104659-15-082184.txt : 20151201 0001104659-15-082184.hdr.sgml : 20151201 20151201144100 ACCESSION NUMBER: 0001104659-15-082184 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20151201 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20151201 DATE AS OF CHANGE: 20151201 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ContraVir Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001583771 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 462783806 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36856 FILM NUMBER: 151262145 BUSINESS ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 BUSINESS PHONE: 732-902-4000 MAIL ADDRESS: STREET 1: 399 THORNALL STREET STREET 2: FIRST FLOOR CITY: EDISON STATE: NJ ZIP: 08837 8-K 1 a15-24375_18k.htm 8-K

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 1, 2015

 

ContraVir Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware

 

001-36856

 

46-2783806

(State or other jurisdiction

 

(Commission

 

IRS Employer

of incorporation or organization)

 

File Number)

 

Identification No.)

 

399 Thornall Street, First Floor

Edison, NJ 08837

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (732) 902-4000

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o  Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


 

Item 8.01                                           Other Events

 

On December 1, 2015, ContraVir Pharmaceuticals, Inc. issued a press release announcing that it will present at HEP DART 2015, held December 6-10, 2015, at the Grand Wailea in Wailea, Hawaii.

 

The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

 

Item 9.01                                           Financial Statements and Exhibits

 

(d) Exhibits

 

99.1                                                                        ContraVir Pharmaceuticals, Inc. Press Release dated December 1, 2015

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated:           December 1, 2015

 

 

 

 

CONTRAVIR PHARMACEUTICALS, INC.

 

 

 

 

 

 

By:

/s/ James Sapirstein

 

 

James Sapirstein

 

 

Chief Executive Officer

 

2

 EX-99.1 2 a15-24375_1ex99d1.htm EX-99.1

Exhibit 99.1

 

ContraVir to Present New CMX157 Data at HEP DART 2015

 

Data to Highlight CMX157’s Significant Potential Compared to Viread® for Treating Hepatitis B

 

EDISON, N.J., Dec. 1, 2015 /PRNewswire/ — ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, announced today that it will present at HEP DART 2015, held December 6-10, 2015, at the Grand Wailea in Wailea, Hawaii. The latest findings further support CMX157’s considerable potential to enhance the safety profile and reduce side effects compared to Gilead’s tenofovir DF (Viread®).

 

John Sullivan-Bolyai, MD, MPH, Chief Medical Officer of ContraVir, will give an oral presentation highlighting preclinical data for CMX157, the Company’s highly potent lipid prodrug of the successful antiviral drug tenofovir (TFV) for treating hepatitis B. CMX157’s enhanced absorption technology utilizes natural lipid uptake pathways to target the liver, resulting in lower systemic exposure to TFV and the potential for reduced off-target TFV toxicity.

 

Title: Efficient Liver Targeting and Uptake by Novel Tenofovir Prodrug, CMX157, for the Treatment of Hepatitis B
Date: Tuesday, December 8, 2015
Time: 6:10pm HST
Location: Grand Wailea Hotel, Hawaii

 

About ContraVir Pharmaceuticals

 

ContraVir is a biopharmaceutical company focused on the discovery and development of targeted antiviral therapies with two candidates in mid-to-late stage clinical development. ContraVir’s lead clinical drug, FV-100, is an orally available nucleoside analogue prodrug that is being developed for the treatment of herpes zoster, or shingles, which is currently in Phase 3 clinical development. In addition to direct antiviral activity, FV-100 has demonstrated the potential to reduce the incidence of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN) in a Phase 2 clinical study. ContraVir is also developing CMX157, a highly potent analog of the successful antiviral drug tenofovir, for the Hepatitis B virus (HBV). CMX157’s novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal and bone side effects.

 

For further information, please contact:

 

Tiberend Strategic Advisors, Inc.

 


 

Tirth Patel (investors) 
tpatel@tiberend.com; (212) 375-2681

 

Claire Sojda (media)
csojda@tiberend.com; (212) 375-2686